Table 1.

MRD status during maintenance therapy, according to patients’ baseline characteristics, and treatment response at the start and after 12 months of maintenance therapy

MRD statusP
Negative, N = 127Positive, N = 382
Age, no. (%), y.14
 <60 y62 (22.4)215 (77.6)
 ≥60 y65 (28.0)167 (72.0)
Sex, no. (%).19
 Male68 (22.8)230 (77.2)
 Female59 (28.0)152 (72.0)
ISS disease stage, no. (%).61
 Stage I38 (23.0)127 (77.0)
 Stage II67 (26.9)182 (73.1)
 Stage III22 (23.2)73 (76.8)
Cytogenetic risk profile, no. (%).40*
 Standard risk85 (26.2)239 (73.8)
 High risk23 (31.1)51 (68.9)
 FISH failure19 (17.1)92 (82.9)
Treatment arm, no. (%).01
 RVD-alone54 (20.5)210 (79.5)
 Transplantation73 (29.8)172 (70.2)
Response at the beginning of maintenance therapy, no. (%).006
 Complete response stringent or not54 (49.5)55 (50.5)
 VGPR36 (31.3)79 (68.7)
 Partial response0 (0.0)134 (100.0)
 Stable disease0 (0.0)8 (100.0)
Response after 12 mo of maintenance therapy, no. (%)<.001
 Complete response stringent or not83 (59.7)56 (40.3)
 VGPR9 (20.5)35 (79.5)
 Partial response0 (0.0)56 (100.0)
  • FISH, fluorescence in situ hybridization.

  • * The FISH failure category was excluded.

  • Among the 127 patients who were MRD during maintenance therapy, 90 achieved negativity at the beginning of maintenance therapy, and 92 after completion of maintenance therapy.

  • Patients who achieved less than a VGPR were excluded.